A Review on Kaempferol Eye Drops for the Glaucoma Treatment

Year : 2025 | Volume : 12 | Issue : 02 | Page : 110 121
    By

    Rushikesh Chandrakant Sorate,

  • Yashan Kishor Gosavi,

  • Ravikant Siddhappa Bandgar,

  • Prerana Prakash Jadhav,

  • Nikita Ganapat Kasurde,

  • Omkar Maruti Ekamalli,

  1. Assistant Professor, Department of Pharmacy, Vijayrao Naik College of Pharmacy, Shirval, Kankavli, Sindhudurg, Maharashtra, India
  2. Student, Department of Pharmacy, Vijayrao Naik College of Pharmacy, Shirval, Kankavli, Sindhudurg, Maharashtra, India
  3. Student, Department of Pharmacy, Vijayrao Naik College of Pharmacy, Shirval, Kankavli, Sindhudurg, Maharashtra, India
  4. Student, Department of Pharmacy, Vijayrao Naik College of Pharmacy, Shirval, Kankavli, Sindhudurg, Maharashtra, India
  5. Student, Department of Pharmacy, Vijayrao Naik College of Pharmacy, Shirval, Kankavli, Sindhudurg, Maharashtra, India
  6. Student, Department of Pharmacy, Vijayrao Naik College of Pharmacy, Shirval, Kankavli, Sindhudurg, Maharashtra, India

Abstract

One of the main causes of permanent blindness, glaucoma is defined by gradual damage to the optic nerve, mostly brought on by oxidative stress, neuroinflammation, and high intraocular pressure (IOP). The investigation of herbal alternatives is necessary since current synthetic therapies, such as beta-blockers and prostaglandin analogs, frequently result in ocular discomfort, systemic toxicity, and poor patient compliance. Clitoria ternatea contains kaempferol, a bioactive flavonoid that has shown anti-inflammatory, antioxidant, and neuroprotective qualities, making it a viable option for treating glaucoma. The molecular mechanisms of Kaempferol in the treatment of glaucoma are examined in this review, with a focus on how it reduces oxidative stress, inhibits IL-1β-mediated neuroinflammation, and improves aqueous humor outflow. Molecular docking studies indicate its promise as an alternative anti-glaucoma treatment by confirming its great binding affinity to important glaucoma-related proteins as matrix metalloproteinase-2 (MMP-2) and carbonic anhydrase II (CA-II). Kaempferol’s benefits over synthetic medications, such as its long-term safety and few adverse effects, are highlighted by comparative studies. In order to maximize Kaempferol’s bioavailability and therapeutic use in ocular formulations, this work emphasizes the necessity of additional computational validation and experimental investigation. Kaempferol-based therapies may offer a safer, more efficient substitute for the treatment of glaucoma by combining contemporary drug discovery methods with herbal pharmacology, therefore bridging the gap between modern pharmacology and traditional medicine.

Keywords: Glaucoma, Kaempferol, Clitoria ternatea, Oxidative Stress, Neuroinflammation, Intraocular Pressure (IOP), Antioxidant, Neuroprotection.

[This article belongs to Trends in Drug Delivery ]

How to cite this article:
Rushikesh Chandrakant Sorate, Yashan Kishor Gosavi, Ravikant Siddhappa Bandgar, Prerana Prakash Jadhav, Nikita Ganapat Kasurde, Omkar Maruti Ekamalli. A Review on Kaempferol Eye Drops for the Glaucoma Treatment. Trends in Drug Delivery. 2025; 12(02):110-121.
How to cite this URL:
Rushikesh Chandrakant Sorate, Yashan Kishor Gosavi, Ravikant Siddhappa Bandgar, Prerana Prakash Jadhav, Nikita Ganapat Kasurde, Omkar Maruti Ekamalli. A Review on Kaempferol Eye Drops for the Glaucoma Treatment. Trends in Drug Delivery. 2025; 12(02):110-121. Available from: https://journals.stmjournals.com/tdd/article=2025/view=215662


References

  1. You Y, Gupta VK, Li JC, Klistorner A, Graham SL. Optic neuropathies: characteristic features and mechanisms of retinal ganglion cell loss. Reviews in the Neurosciences. 2013;24(3):301-21.
  2. Marín O. Developmental timing and critical windows for the treatment of psychiatric disorders. Nature medicine. 2016;22(11):1229-38.
  3. Ciobanu AM, Dionisie V, Neagu C, Bolog OM, Riga S, Popa-Velea O. Psychopharmacological treatment, intraocular pressure and the risk of glaucoma: a review of literature. Journal of Clinical Medicine. 2021;10(13):2947.
  4. Liu S-A, Zhao Z-N, Sun N-N, Han Y, Chen J, Fan Z-G. Transitions of the understanding and definition of primary glaucoma. Chinese medical journal. 2018;131(23):2852-9.
  5. Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nature Reviews Drug Discovery. 2023;22(5):387-409.
  6. Shoaib S, Ansari MA, Fatease AA, Safhi AY, Hani U, Jahan R, et al. Plant-derived bioactive compounds in the management of neurodegenerative disorders: challenges, future directions and molecular mechanisms involved in neuroprotection. Pharmaceutics. 2023;15(3):749.
  7. Weinreb RN, Toris CB, B’Ann TG, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Survey of ophthalmology. 2002;47:S53-S64.
  8. Rittenhouse KD. Beta-blocker modulation of aqueous humor production: The University of North Carolina at Chapel Hill; 1999.
  9. Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opinion on Therapeutic Patents. 2000;10(5):575-600.
  10. Adkins JC, Balfour JA. Brimonidine: a review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs & aging. 1998;12:225-41.
  11. Fraunfelder FT, Fraunfelder FW, Chambers WA. Drug-Induced Ocular Side effects: clinical ocular toxicology E-Book: clinical ocular toxicology: Elsevier Health Sciences; 2014.
  12. Iriti M, Vitalini S, Fico G, Faoro F. Neuroprotective herbs and foods from different traditional medicines and diets. Molecules. 2010;15(5):3517-55.
  13. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Progress in retinal and eye research. 2006;25(5):490-513.
  14. Makasana J, Dholakiya BZ, Gajbhiye NA, Raju S. Extractive determination of bioactive flavonoids from butterfly pea (Clitoria ternatea Linn.). Research on Chemical Intermediates. 2017;43:783-99.
  15. Shafie A, Khan S, Zehra, Mohammad T, Anjum F, Hasan GM, et al. Identification of phytoconstituents as potent inhibitors of casein kinase-1 alpha using virtual screening and molecular dynamics simulations. Pharmaceutics. 2021;13(12):2157.
  16. Adams CM, Stacy R, Rangaswamy N, Bigelow C, Grosskreutz CL, Prasanna G. Glaucoma-next generation therapeutics: impossible to possible. Pharmaceutical research. 2019;36:1-17.
  17. Jaiswal Y, Liang Z, Zhao Z. Botanical drugs in Ayurveda and traditional Chinese medicine. Journal of ethnopharmacology. 2016;194:245-59.
  18. Sim RH, Sirasanagandla SR, Das S, Teoh SL. Treatment of glaucoma with natural products and their mechanism of action: An update. Nutrients. 2022;14(3):534.
  19. Cohen K, Weinstein AM. Synthetic and non-synthetic cannabinoid drugs and their adverse effects-a review from public health prospective. Frontiers in public health. 2018;6:162.
  20. Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: A review. European journal of medicinal chemistry. 2015;97:55-74.
  21. Schmidt K-G, Bergert H, Funk R. Neurodegenerative diseases of the retina and potential for protection and recovery. Current neuropharmacology. 2008;6(2):164-78.
  22. Smith AF, Brown GC. Understanding cost effectiveness: a detailed review. British Journal of Ophthalmology. 2000;84(7):794-8.
  23. Aihara M, Iwase A, Fernando S, Kook MS, Law S, Nussenblatt R, et al. Non-pharmaceutical medications and approaches to glaucoma (all articles).
  24. Okoduwa SI, Abdulwaliyu I, Igiri BE, Arekemase SO, Okoduwa UJ, Itiat JF, et al. Multi-therapeutic potential of flavonoids as an essential component in nutraceuticals for the treatment and management of human diseases. Phytomedicine Plus. 2024:100558.
  25. Raina K, Chauhan A, Sharma R, Thakur S, Chaudhary A. Role of Antidepressant Agents Derived from Selected Flowering Plants. Himalayan Medicinal Plants for the Treatment of Depression: Apple Academic Press; 2025. p. 99-128.
  26. Ahmed N, Tabassum N, Rashid PT, Deea BJ, Richi FT, Chandra A, et al. Clitoria ternatea L.(Butterfly Pea) Flower Against Endometrial Pain: Integrating Preliminary In Vivo and In Vitro Experimentations Supported by Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation Studies. Life. 2024;14(11):1473.
  27. Ames BN, Profet M, Gold LS. Nature’s chemicals and synthetic chemicals: comparative toxicology. Proceedings of the National Academy of Sciences. 1990;87(19):7782-6.
  28. Sharifi-Rad J, Rapposelli S, Sestito S, Herrera-Bravo J, Arancibia-Diaz A, Salazar LA, et al. Multi-target mechanisms of phytochemicals in Alzheimer’s disease: Effects on oxidative stress, neuroinflammation and protein aggregation. Journal of Personalized Medicine. 2022;12(9):1515.
  29. Bloom BS. Daily regimen and compliance with treatment: fewer daily doses and drugs with fewer side effects improve compliance. British Medical Journal Publishing Group; 2001. p. 647.
  30. Ahmed SN, Ahmad M, Zafar M, Yaseen G, Iqbal N, Rashid N, et al. Herbal drugs: safety, cost-effectiveness, regulation, current trends, and future directions. Bioprospecting of Tropical Medicinal Plants: Springer; 2023. p. 1479-93.
  31. Kyriakoudi A, Spanidi E, Mourtzinos I, Gardikis K. Innovative delivery systems loaded with plant bioactive ingredients: Formulation approaches and applications. Plants. 2021;10(6):1238.
  32. Oguis GK, Gilding EK, Jackson MA, Craik DJ. Butterfly pea (Clitoria ternatea), a cyclotide-bearing plant with applications in agriculture and medicine. Frontiers in plant science. 2019;10:645.
  33. Adornetto A, Rombolà L, Morrone LA, Nucci C, Corasaniti MT, Bagetta G, et al. Natural products: evidence for neuroprotection to be exploited in glaucoma. Nutrients. 2020;12(10):3158.
  34. Al-Snafi AE. Pharmacological importance of Clitoria ternatea–A review. IOSR journal of Pharmacy. 2016;6(3):68-83.
  35. Abd Rashid N, Mohammed SNF, Syed Abd Halim SA, Ghafar NA, Abdul Jalil NA. Therapeutic potential of honey and propolis on ocular disease. Pharmaceuticals. 2022;15(11):1419.
  36. Jeyaraj EJ, Lim YY, Choo WS. Extraction methods of butterfly pea (Clitoria ternatea) flower and biological activities of its phytochemicals. Journal of food science and technology. 2021;58(6):2054-67.
  37. Wu J, Gong J, Chen Q, Hao W, He J, Wang M, et al. Unveiling kaempferol glycosides as the key antiglycative components in butterfly pea (Clitoria ternatea) flower. Current Research in Food Science. 2024;9:100896.
  38. Majumdar S, Srirangam R. Potential of the bioflavonoids in the prevention/treatment of ocular disorders. Journal of pharmacy and pharmacology. 2010;62(8):951-65.
  39. Al Sabaani N. Kaempferol protects against hydrogen peroxide-induced retinal pigment epithelium cell inflammation and apoptosis by activation of SIRT1 and inhibition of PARP1. Journal of Ocular Pharmacology and Therapeutics. 2020;36(7):563-77.
  40. Fanaro GB, Marques MR, Calaza KdC, Brito R, Pessoni AM, Mendonça HR, et al. New insights on dietary polyphenols for the Management of Oxidative Stress and Neuroinflammation in diabetic retinopathy. Antioxidants. 2023;12(6):1237.
  41. Krstić L, González-García MJ, Diebold Y. Ocular delivery of polyphenols: meeting the unmet needs. Molecules. 2021;26(2):370.
  42. Baltmr A. An investigation into pro-apoptotic targets in experimental glaucoma and the neuroprotective effects of Ginkgo biloba in retinal ganglion cells: UCL (University College London); 2012.
  43. Hussain MS, Altamimi ASA, Afzal M, Almalki WH, Kazmi I, Alzarea SI, et al. Kaempferol: Paving the path for advanced treatments in aging-related diseases. Experimental gerontology. 2024;188:112389.
  44. Kim JK, Park SU. Recent studies on kaempferol and its biological and pharmacological activities. EXCLI journal. 2020;19:627.
  45. Abdeyazdan S, Mohajeri M, Saberi S, Mirzaei M, Ayatollahi SA, Saghaei L, et al. Sb (V) kaempferol and quercetin derivative complexes: Synthesis, characterization and antileishmanial activities. Iranian Journal of Pharmaceutical Research: IJPR. 2022;21(1):e128379.
  46. Das S. 16 Recent Advancement. Applications of Nanotechnology in Biomedical Engineering. 2024:319.
  47. Ganjali M, Ganjali M, Aljabali AA, Barhoum A. Drug delivery systems based on nano-herbal medicine. Bionanotechnology: Emerging Applications of Bionanomaterials: Elsevier; 2022. p. 491-530.
  48. Kumar A, Shukla R. Current strategic arsenal and advances in nose to brain nanotheranostics for therapeutic intervention of glioblastoma multiforme. Journal of Biomaterials Science, Polymer Edition. 2025;36(2):212-46.
  49. Chaudhuri A, Gauttam VK, Arushi A, Negi S, Singh G, Bharti B, et al. Design and Evaluation of Novel in situ Gel Forming Ocular Drug Delivery System of Kaempferol for Sustain Pharmacological Response against Cataract. Pharmacognosy Research. 2025;17(1).
  50. Ghosh D, Mukherjee PK. Natural medicines: clinical efficacy, safety and quality: CRC Press; 2019.
  51. Alrumaihi F, Almatroodi SA, Alharbi HOA, Alwanian WM, Alharbi FA, Almatroudi A, et al. Pharmacological potential of kaempferol, a flavonoid in the management of pathogenesis via modulation of inflammation and other biological activities. Molecules. 2024;29(9):2007.
  52. Nezhad Salari AM, Rasoulizadeh Z, Shabgah AG, Vakili‐Ghartavol R, Sargazi G, Gholizadeh Navashenaq J. Exploring the mechanisms of kaempferol in neuroprotection: Implications for neurological disorders. Cell Biochemistry and Function. 2024;42(2):e3964.
  53. Sandhu P, Singh B, Gupta V, Bansal P, Kumar D. Potential herbs used in ocular diseases. Journal of pharmaceutical sciences and research. 2011;3(4):1127.
  54. Bujak T, Zagórska-Dziok M, Ziemlewska A, Nizioł-Łukaszewska Z, Lal K, Wasilewski T, et al. Flower extracts as multifunctional dyes in the cosmetics industry. Molecules. 2022;27(3):922.
  55. Wang SK, Chang RT. An emerging treatment option for glaucoma: Rho kinase inhibitors. Clinical ophthalmology. 2014:883-90.
  56. Velusamy S, Rathinavel L. Advancements in Neuroprotection for Glaucoma: Insights into Genes, Mechanisms, Diagnosis, Chemical and Plant-Based Compounds for Therapies.
  57. Huang H-Y, Wang M-C, Chen Z-Y, Chiu W-Y, Chen K-H, Lin I-C, et al. Gelatin–epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief. International Journal of Nanomedicine. 2018:7251-73.
  58. Anthika B, Kusumocahyo SP, Sutanto H. Ultrasonic approach in Clitoria ternatea (butterfly pea) extraction in water and extract sterilization by ultrafiltration for eye drop active ingredient. Procedia Chemistry. 2015;16:237-44.
  59. Lijon MB, Meghla NS, Jahedi E, Rahman MA, Hossain I. Phytochemistry and pharmacological activities of Clitoria ternatea. International Journal of Natural and Social Sciences. 2017;4(1):1-10.
  60. Bennett NH, Chinnery HR, Downie LE, Hill LJ, Grover LM. Material, immunological, and practical perspectives on eye drop formulation. Advanced Functional Materials. 2020;30(14):1908476.
  61. Cáceres-Vélez PR, Hui F, Hercus J, Bui B, Jusuf PR. Restoring the oxidative balance in age-related diseases–an approach in glaucoma. Ageing Research Reviews. 2022;75:101572.
  62. Firenzuoli F, Gori L. Herbal medicine today: clinical and research issues. Evidence‐Based Complementary and Alternative Medicine. 2007;4:37-40.
  63. Hedengran A, Steensberg AT, Virgili G, Azuara-Blanco A, Kolko M. Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis. British Journal of Ophthalmology. 2020;104(11):1512-8.
  64. Rasmussen CA, Kaufman PL, Kiland JA. Benzalkonium chloride and glaucoma. Journal of Ocular Pharmacology and Therapeutics. 2014;30(2-3):163-9.
  65. Rhee DJ, Katz LJ, Spaeth GL, Myers JS. Complementary and alternative medicine for glaucoma. Survey of ophthalmology. 2001;46(1):43-55.
  66. Hossain CM, Gera M, Ali KA. Current status and challenges of herbal drug development and regulatory aspect: a global perspective. Asian J Pharm Clin Res. 2022;15:31-41.
  67. Baranowski P, Karolewicz B, Gajda M, Pluta J. Ophthalmic drug dosage forms: characterisation and research methods. The Scientific World Journal. 2014;2014(1):861904.
  68. Razavi MS, Ebrahimnejad P, Fatahi Y, D’Emanuele A, Dinarvand R. Recent developments of nanostructures for the ocular delivery of natural compounds. Frontiers in chemistry. 2022;10:850757.
  69. Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. British Journal of Ophthalmology. 2020;104(1):2-7.
  70. He T-T, Ung COL, Hu H, Wang Y-T. Good manufacturing practice (GMP) regulation of herbal medicine in comparative research: China GMP, cGMP, WHO-GMP, PIC/S and EU-GMP. european Journal of integrative Medicine. 2015;7(1):55-66.
  71. Masota NE, Vogg G, Ohlsen K, Holzgrabe U. Reproducibility challenges in the search for antibacterial compounds from nature. PLoS One. 2021;16(7):e0255437.
  72. Gafner S, Bergeron C. The challenges of chemical stability testing of herbal extracts in finished products using state-of-the-art analytical methodologies. Current Pharmaceutical Analysis. 2005;1(2):203-15.
  73. López-Paniagua M, de la Mata A, Galindo S, Blázquez F, Calonge M, Nieto-Miguel T. Advanced therapy medicinal products for the eye: Definitions and regulatory framework. Pharmaceutics. 2021;13(3):347.
  74. Abel R. The Eye Care Revolution:: Prevent And Reverse Common Vision Problems, Revised And Updated: Kensington Books; 2014.
  75. Bergamini M. The Drug Discovery Process: How Do New Glaucoma Medications Come to Market? The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care. 2010:961-75.
  76. Organization WH. WHO guidelines on good agricultural and collection practices [GACP] for medicinal plants: World Health Organization; 2003.
  77. BT MN, Tripathi S, Koli S, Kumar AR. Vital Discoveries: Breakthroughs in Pharma and Health Science. 2024.
  78. Bu H-Z, Gukasyan HJ, Goulet L, Lou X-J, Xiang C, Koudriakova T. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Current drug metabolism. 2007;8(2):91-107.
  79. Dainelli R, Bruno A, Martinelli M, Moroni D, Rocchi L, Morelli S, et al. GranoScan: an AI-powered mobile app for in-field identification of biotic threats of wheat. Frontiers in Plant Science. 2024;15:1298791.
  80. Bommakanti V, Puthenparambil Ajikumar A, Sivi CM, Prakash G, Mundanat AS, Ahmad F, et al. An overview of herbal nutraceuticals, their extraction, formulation, therapeutic effects and potential toxicity. Separations. 2023;10(3):177.
Regular Issue Subscription Review Article
Volume 12
Issue 02
Received 09/04/2025
Accepted 17/06/2025
Published 02/07/2025
Publication Time 84 Days
120

Login


My IP

PlumX Metrics